trending Market Intelligence /marketintelligence/en/news-insights/trending/ap353dfhfmcxwe7prx9gua2 content esgSubNav
In This List

Sage Therapeutics' depression drug receives US FDA priority review

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sage Therapeutics' depression drug receives US FDA priority review

Sage Therapeutics Inc. said the U.S. Food and Drug Administration granted priority review to its new drug application for brexanolone, a medicine for postpartum depression.

Postpartum depression is a major depressive disorder that is the most common medical complication of childbirth, affecting a subset of women typically commencing in the third trimester of pregnancy or within four weeks after giving birth.

The Cambridge, Mass.-based company said the FDA will make a decision on the application by Dec. 19.